Plain-English translation of NCT06117384 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This research study is collecting samples—including tumor tissue, fluid from the abdomen, and blood—from patients with ovarian cancer. Researchers will analyze these samples using advanced genetic and laboratory techniques to understand why some ovarian cancers stop responding to chemotherapy and to discover new treatment approaches that might help patients.
Ovarian cancer often becomes resistant to standard chemotherapy treatments, leaving patients with limited options. This study exists to uncover the biological reasons behind this resistance so doctors can develop better, more personalized treatment strategies for future ovarian cancer patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would donate samples—such as tumor tissue, abdominal fluid, and blood—at specific timepoints during your ovarian cancer treatment. Researchers will then analyze these samples in the laboratory using advanced sequencing and functional testing to understand your individual cancer's characteristics. The study is observational, meaning you continue your regular cancer care while contributing samples to help improve future treatment options.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Finland
University of Helsinki
Collaborators
Helsinki University Central Hospital
Enrollment target
~500 participants
Started
January 2022
Primary completion
December 2027
Sex
Female only
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anniina Färkkilä, MD PhD
Helsinki University Central Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.